A型肉毒素治疗银屑病一例并文献复习
|
摘要
有文献报道A型肉毒素治疗顽固性斑块型银屑病和反转型银屑病效果较好。本文报道A型肉毒素治疗斑块型银屑病患者一例并对相关文献进行复习。患者右小腿外侧皮损作为靶皮损(PASI=7分),注射A型肉毒素,臀部皮损(PASI=6分)为对照靶皮损,无特殊治疗。A型肉毒素注射1个月后回访,右小腿皮疹明显好转,PASI=1分;臀部对照皮损,无明显好转,PASI=5分。
It was reported that Botulinum toxin type-A was effective for treating recalcitrant plaque psoriasis and inverse psoriasis. One patient with plaque psoriasis treated with Botulinum toxin type-A was reported in this paper and related literatures were reviewed. The lesions on the right calf was treated by Botulinum toxin type-A and that on the buttock was as control, with no treatment. The lesion treated by Botulinum toxin type-A improved markedly and the PASI score reduced from 7 to 1 after one month, while the control lesion did not have obvious improvement the PASI score reduced from 6 to 5.
It was reported that Botulinum toxin type-A was effective for treating recalcitrant plaque psoriasis and inverse psoriasis. One patient with plaque psoriasis treated with Botulinum toxin type-A was reported in this paper and related literatures were reviewed. The lesions on the right calf was treated by Botulinum toxin type-A and that on the buttock was as control, with no treatment. The lesion treated by Botulinum toxin type-A improved markedly and the PASI score reduced from 7 to 1 after one month, while the control lesion did not have obvious improvement the PASI score reduced from 6 to 5.
引文
[1] Boehncke WH, Schon MP. Psoriasis[J]. Lancet,2015,386(9997):983-994.
[2] Campanati A, Martina E, Giuliodori K, et al. Botulinum toxin off-label use in dermatology: a review[J]. Skin Appendage Disord,2017,3(1):39-56.
[3] Carmichael NM, Dostrovsky JO, Charlton MP. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin[J]. Pain,2010,149(2):316-324.
[4] Wang TS, Tsai TF. Intralesional therapy for psoriasis[J]. J Dermatolog Treat,2013,24(5):340-347.
[5] Giordano CN, Matarasso SL, Ozog DM. Injectable and topical neurotoxins in dermatology: Basic science, anatomy, and therapeutic agents[J]. J Am Acad Dermatol,2017,76(6):1013-1024.
[6] 屈园园, 孙志文, 康晓静. A型肉毒毒素联合2940nm点阵激光治疗面部皱纹的疗效评价[J].中国麻风皮肤病杂志,2017,33(10):614-616.
[7] 吴艳, 朱学骏. A型肉毒毒素在面部除皱方面的应用[J].中国麻风皮肤病杂志,2003,19(5):466-468.
[8] 钟绮丽,徐娟,程滨珠,等.A型肉毒毒素消除面部皱纹100例临床观察[J].中国麻风皮肤病杂志,2004,20(1):12-14.
[9] 曹庆科, 邓佳, 于志湖. A型肉毒毒素治疗多汗症研究进展[J].中国麻风皮肤病杂志,2006,22(12):1009-1011.
[10] 朱明明, 刘科峰. A型肉毒毒素治疗带状疱疹后遗神经痛疗效评价[J].中国麻风皮肤病杂志, 2018,34(8):473-474.
[11] Farber EM, Lanigan SW, Boer J. The role of cutaneous sensory nerves in the maintenance of psoriasis[J]. Int J Dermatol,1990,29(6):418-420.
[12] Zhu TH, Nakamura M, Farahnik B, et al. The Role of the nervous system in the pathophysiology of psoriasis: A review of cases of psoriasis remission or improvement following denervation injury[J]. Am J Clin Dermatol,2016,17(3):257-263.
[13] Ostrowski SM, Belkadi A, Loyd CM, et al. Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflammation in a sensory neuropeptide-dependent manner[J]. J Invest Dermatol,2011,131(7):1530-1538.
[14] Saraceno R, Kleyn CE, Terenghi G, et al. The role of neuropeptides in psoriasis[J]. Br J Dermatol,2006,155(5):876-882.
[15] Blanco L, Ordovas-Montanes J, Perro M, et al. Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation[J]. Nature,2014,510(7503):157-161.
[16] Ryan C, Abramson A, Patel M, et al. Current investigational drugs in psoriasis[J]. Expert Opin Investig Drugs,2012,21(4):473-487.
[17] Raychaudhuri SP, Jiang WY, Smoller BR, et al. Nerve growth factor and its receptor system in psoriasis[J]. Br J Dermatol,2000,143(1):198-200.
[18] Rukwied RR, Main M, Weinkauf B, et al. NGF sensitizes nociceptors for cowhage- but not histamine-induced itch in human skin[J]. J Invest Dermatol,2013,133(1):268-270.
[19] Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis[J]. Acta Derm Venereol,2015,95(5):542-548.
[20] Ward NL, Kavlick KD, Diaconu D, et al. Botulinum neurotoxin A decreases infiltrating cutaneous lymphocytes and improves acanthosis in the KC-Tie2 mouse model[J]. J Invest Dermatol,2012,132(7):1927-1930.
[21] Gilbert E, Ward NL. Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis[J]. J Drugs Dermatol,2014,13(11):1407-1408.
[22] Saber M, Brassard D, Benohanian A. Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A[J]. Arch Dermatol,2011,147(5):629-630.
[23] Zanchi M, Favot F, Bizzarini M, et al. Botulinum toxin type-A for the treatment of inverse psoriasis[J]. J Eur Acad Dermatol Venereol,2008,22(4):431-436.
[24] Wallengren J, Bartosik J. Botulinum toxin type A for neuropathic itch[J]. Br J Dermatol,2010,163(2):424-426.
[25] Todberg T, Zachariae C, Bregnhoj A, et al. The effect of botulinum neurotoxin A in patients with plaque psoriasis - an exploratory trial[J]. J Eur Acad Dermatol Venereol,2018,32(2):e81-e82.
[26] Bagherani N, Smoller BR. The efficacy of botulinum neurotoxin A in the treatment of plaque psoriasis[J]. Dermatol Ther,2018,31(2):e12587.
[27] Giordano CN, Matarasso SL, Ozog DM. Injectable and topical neurotoxins in dermatology: Indications, adverse events, and controversies[J]. J Am Acad Dermatol,2017,76(6):1027-1042.
[2] Campanati A, Martina E, Giuliodori K, et al. Botulinum toxin off-label use in dermatology: a review[J]. Skin Appendage Disord,2017,3(1):39-56.
[3] Carmichael NM, Dostrovsky JO, Charlton MP. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin[J]. Pain,2010,149(2):316-324.
[4] Wang TS, Tsai TF. Intralesional therapy for psoriasis[J]. J Dermatolog Treat,2013,24(5):340-347.
[5] Giordano CN, Matarasso SL, Ozog DM. Injectable and topical neurotoxins in dermatology: Basic science, anatomy, and therapeutic agents[J]. J Am Acad Dermatol,2017,76(6):1013-1024.
[6] 屈园园, 孙志文, 康晓静. A型肉毒毒素联合2940nm点阵激光治疗面部皱纹的疗效评价[J].中国麻风皮肤病杂志,2017,33(10):614-616.
[7] 吴艳, 朱学骏. A型肉毒毒素在面部除皱方面的应用[J].中国麻风皮肤病杂志,2003,19(5):466-468.
[8] 钟绮丽,徐娟,程滨珠,等.A型肉毒毒素消除面部皱纹100例临床观察[J].中国麻风皮肤病杂志,2004,20(1):12-14.
[9] 曹庆科, 邓佳, 于志湖. A型肉毒毒素治疗多汗症研究进展[J].中国麻风皮肤病杂志,2006,22(12):1009-1011.
[10] 朱明明, 刘科峰. A型肉毒毒素治疗带状疱疹后遗神经痛疗效评价[J].中国麻风皮肤病杂志, 2018,34(8):473-474.
[11] Farber EM, Lanigan SW, Boer J. The role of cutaneous sensory nerves in the maintenance of psoriasis[J]. Int J Dermatol,1990,29(6):418-420.
[12] Zhu TH, Nakamura M, Farahnik B, et al. The Role of the nervous system in the pathophysiology of psoriasis: A review of cases of psoriasis remission or improvement following denervation injury[J]. Am J Clin Dermatol,2016,17(3):257-263.
[13] Ostrowski SM, Belkadi A, Loyd CM, et al. Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflammation in a sensory neuropeptide-dependent manner[J]. J Invest Dermatol,2011,131(7):1530-1538.
[14] Saraceno R, Kleyn CE, Terenghi G, et al. The role of neuropeptides in psoriasis[J]. Br J Dermatol,2006,155(5):876-882.
[15] Blanco L, Ordovas-Montanes J, Perro M, et al. Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation[J]. Nature,2014,510(7503):157-161.
[16] Ryan C, Abramson A, Patel M, et al. Current investigational drugs in psoriasis[J]. Expert Opin Investig Drugs,2012,21(4):473-487.
[17] Raychaudhuri SP, Jiang WY, Smoller BR, et al. Nerve growth factor and its receptor system in psoriasis[J]. Br J Dermatol,2000,143(1):198-200.
[18] Rukwied RR, Main M, Weinkauf B, et al. NGF sensitizes nociceptors for cowhage- but not histamine-induced itch in human skin[J]. J Invest Dermatol,2013,133(1):268-270.
[19] Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis[J]. Acta Derm Venereol,2015,95(5):542-548.
[20] Ward NL, Kavlick KD, Diaconu D, et al. Botulinum neurotoxin A decreases infiltrating cutaneous lymphocytes and improves acanthosis in the KC-Tie2 mouse model[J]. J Invest Dermatol,2012,132(7):1927-1930.
[21] Gilbert E, Ward NL. Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis[J]. J Drugs Dermatol,2014,13(11):1407-1408.
[22] Saber M, Brassard D, Benohanian A. Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A[J]. Arch Dermatol,2011,147(5):629-630.
[23] Zanchi M, Favot F, Bizzarini M, et al. Botulinum toxin type-A for the treatment of inverse psoriasis[J]. J Eur Acad Dermatol Venereol,2008,22(4):431-436.
[24] Wallengren J, Bartosik J. Botulinum toxin type A for neuropathic itch[J]. Br J Dermatol,2010,163(2):424-426.
[25] Todberg T, Zachariae C, Bregnhoj A, et al. The effect of botulinum neurotoxin A in patients with plaque psoriasis - an exploratory trial[J]. J Eur Acad Dermatol Venereol,2018,32(2):e81-e82.
[26] Bagherani N, Smoller BR. The efficacy of botulinum neurotoxin A in the treatment of plaque psoriasis[J]. Dermatol Ther,2018,31(2):e12587.
[27] Giordano CN, Matarasso SL, Ozog DM. Injectable and topical neurotoxins in dermatology: Indications, adverse events, and controversies[J]. J Am Acad Dermatol,2017,76(6):1027-1042.